 Central Nervous System Agents
"Central Nervous System Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)
| Descriptor ID |
D002491
|
| MeSH Number(s) |
D27.505.954.427
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Agents".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Agents".
This graph shows the total number of publications written about "Central Nervous System Agents" by people in this website by year, and whether "Central Nervous System Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Central Nervous System Agents" by people in Profiles.
-
Writer JH, Antweiler RC, Ferrer I, Ryan JN, Thurman EM. In-stream attenuation of neuro-active pharmaceuticals and their metabolites. Environ Sci Technol. 2013 Sep 03; 47(17):9781-90.
-
Writer JH, Ferrer I, Barber LB, Thurman EM. Widespread occurrence of neuro-active pharmaceuticals and metabolites in 24 Minnesota rivers and wastewaters. Sci Total Environ. 2013 Sep 01; 461-462:519-27.
-
Linnebur SA, Vande Griend JP, Dugan JP, Page RL. Positive Beers criteria: limitations. Consult Pharm. 2009 Nov; 24(11):792; author reply 792, 794.
-
Hall DA, Berry-Kravis E, Hagerman RJ, Hagerman PJ, Rice CD, Leehey MA. Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. Mov Disord. 2006 Oct; 21(10):1741-4.
-
O'Connor KA, Hansen MK, Rachal Pugh C, Deak MM, Biedenkapp JC, Milligan ED, Johnson JD, Wang H, Maier SF, Tracey KJ, Watkins LR. Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects. Cytokine. 2003 Dec 21; 24(6):254-65.
-
Arciniegas DB, Topkoff J. The neuropsychiatry of pathologic affect: an approach to evaluation and treatment. Semin Clin Neuropsychiatry. 2000 Oct; 5(4):290-306.
-
Franson KL, Hay DP, Neppe V, Dahdal WY, Mirza WU, Grossberg GT, Chatel DM, Szwabo PA, Kotegal S. Drug-induced seizures in the elderly. Causative agents and optimal management. Drugs Aging. 1995 Jul; 7(1):38-48.
-
Filley CM, Kelly JP. Alcohol- and drug-related neurotoxicity. Curr Opin Neurol Neurosurg. 1993 Jun; 6(3):443-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|